PMID- 17545797
OWN - NLM
STAT- MEDLINE
DCOM- 20071012
LR  - 20211124
IS  - 1040-8746 (Print)
IS  - 1040-8746 (Linking)
VI  - 19
IP  - 4
DP  - 2007 Jul
TI  - Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.
PG  - 341-6
AB  - PURPOSE OF REVIEW: The most recent developments regarding chemotherapy treatment 
      of osteogenic sarcoma are reviewed, with special emphasis on prospective clinical 
      trials and evaluations of late effects of chemotherapy. RECENT FINDINGS: In 
      recent years, clinical research has essentially focused on possible refinements 
      of the classic four-drug (methotrexate, cisplatin, doxorubicin and ifosfamide) 
      therapy rather than investigating new drugs. It has been demonstrated that 
      dose-intensification does not improve prognosis. Many investigators have 
      evaluated late chemotherapy-related side effects, particularly in terms of 
      cardiac, renal and auditive toxicity, risk of infertility and of second tumors. 
      Recent findings recommend further studies to define the role of the 
      immunostimulating agent muramyl tripeptide-phosphatidilethanolamine in 
      osteosarcoma. Preclinical and phase II studies suggest an activity of mammalian 
      target of rapamycin (mTOR) inhibitors in osteosarcoma, which also deserves 
      further clinical studies. SUMMARY: At present, patients with nonmetastatic 
      osteosarcoma of the extremity aged less than 40 years have an expected 5-year 
      survival rate of 70% with a chemotherapy regimen based on methotrexate, 
      cisplatin, doxorubicin and ifosfamide. Further improvement cannot be achieved by 
      dose intensification of treatment and new strategies are required. Prolonged 
      follow-up is mandatory due to the risk of late effects, second tumors and late 
      relapse from osteosarcoma.
FAU - Ferrari, Stefano
AU  - Ferrari S
AD  - Chemotherapy Department, Istituto Ortopedico Rizzoli, Bologna, Italy. 
      stefano.ferrari@ior.it
FAU - Palmerini, Emanuela
AU  - Palmerini E
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Oncol
JT  - Current opinion in oncology
JID - 9007265
RN  - 0 (Adjuvants, Pharmaceutic)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - UM20QQM95Y (Ifosfamide)
SB  - IM
MH  - Adjuvants, Pharmaceutic
MH  - Antineoplastic Agents, Alkylating/therapeutic use
MH  - Bone Neoplasms/*drug therapy/mortality/pathology
MH  - *Chemotherapy, Adjuvant
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Ifosfamide/therapeutic use
MH  - *Neoadjuvant Therapy
MH  - Osteosarcoma/*drug therapy/mortality/pathology
MH  - Time Factors
RF  - 36
EDAT- 2007/06/05 09:00
MHDA- 2007/10/13 09:00
CRDT- 2007/06/05 09:00
PHST- 2007/06/05 09:00 [pubmed]
PHST- 2007/10/13 09:00 [medline]
PHST- 2007/06/05 09:00 [entrez]
AID - 00001622-200707000-00010 [pii]
AID - 10.1097/CCO.0b013e328122d73f [doi]
PST - ppublish
SO  - Curr Opin Oncol. 2007 Jul;19(4):341-6. doi: 10.1097/CCO.0b013e328122d73f.